Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to growth in LENVIMA, LEQEMBI and DAYVIGO, as well as the weaker yen. Operating profit absorbed the impact of distributor inventory build-up in China in the same quarter of the previous year through growth in major products. Selling, general and administrative expenses increased due to payments of shared profits for LENVIMA and investment of resources in LEQEMBI, while research and development expenses increased due to the active allocation of resources to important projects.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 234,330 Millions of yen (YoY +15.6%) |
| Operating profit | 24,728 Millions of yen (YoY +19.2%) |
| Ordinary income | 25,283 Millions of yen (YoY +12.8%) |
| Profit attributable to owners of the parent | 18,242 Millions of yen (YoY +26.0%) |
| Net income per share | ¥64.71 |
| Equity ratio | End of the current fiscal period 58.2 / End of previous period 62 |
| Total assets | 1,558,091 Millions of yen |
| Net assets | 933,169 Millions of yen |
| Cash flows from operating activities | -2,588 Millions of yen |
| Cash flows from investing activities | 6,457 Millions of yen |
| Cash flows from financing activities | 57,925 Millions of yen |
| Cash and cash equivalents at end of period | 311,739 Millions of yen |
| Full-year earnings forecast | Net Sales 883,500 Millions of yen (YoY +7.0%) / Operating profit 70,000 Millions of yen (YoY +58.6%) / Ordinary income 74,000 Millions of yen (YoY +45.1%) / Net income 54,000 Millions of yen (YoY +33.3%) / Profit for the period attributable to owners of the parent 52,300 Millions of yen (YoY +35.6%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥160 → ¥160（0.0%） |
| Segment revenue | Japan 57,940 Millions of yen (YoY +3.4%), Americas 86,576 Millions of yen (YoY +22.3%), China 42,527 Millions of yen (YoY +16.6%), EMEA 23,646 Millions of yen (YoY +24.4%), East Asia and Global South 20,212 Millions of yen (YoY +25.3%) |
| Segment profit | Japan 21,032 Millions of yen (YoY +8.1%), Americas 51,936 Millions of yen (YoY +25.0%), China 21,178 Millions of yen (YoY +18.2%), EMEA 12,451 Millions of yen (YoY +51.8%), East Asia and Global South 9,481 Millions of yen (YoY +15.0%) |
| Regional sales | 57,940 Millions of yen (YoY +3.4%), 86,576 Millions of yen (YoY +22.3%), 42,527 Millions of yen (YoY +16.6%), 23,646 Millions of yen (YoY +24.4%), 20,212 Millions of yen (YoY +25.3%) |
| Depreciation and amortization | 9,420 Millions of yen |
| Impairment loss | No impairment loss was recorded in the current first quarter (impairment loss in the statement of cash flows is shown as “—”). |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 291,649,149 |
| Treasury Shares at Period-End | 9,190,146 |
| Factors Behind Changes in Business Performance | Revenue increased due to growth in LENVIMA, LEQEMBI and DAYVIGO, as well as the weaker yen. Operating profit absorbed the impact of distributor inventory build-up in China in the same quarter of the previous year through growth in major products. Selling, general and administrative expenses increased due to payments of shared profits for LENVIMA and investment of resources in LEQEMBI, while research and development expenses increased due to the active allocation of resources to important projects. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from LENVIMA, LEQEMBI and DAYVIGO increased, while the weaker yen also contributed to higher revenue. Operating profit absorbed the impact of distributor inventory build-up in China in the same quarter of the previous year through growth in major products. Meanwhile, selling, general and administrative expenses and research and development expenses increased due to payments of shared profits for LENVIMA and investment of resources in LEQEMBI and other products.